Sharing our knowledge of melanoma on the global stage
15 April 2021
More than 2,000 clinicians and researchers from across the globe will unite online this weekend for the virtual 10th World Congress of Melanoma in conjunction with the 17th EADO Congress.
As leaders in the field of melanoma, many clinicians and researchers from Melanoma Institute Australia (MIA) will be sharing their knowledge as this congress provides an opportunity to educate clinicians on the latest developments in our understanding and treatment of skin cancer.
Here are just a handful of the areas of melanoma research that we will be presenting on:
- Renowned pathologist and MIA’s Co-Medical Director, Prof Richard Scolyer, will discuss how we can predict the likelihood that a patient’s disease will return by examining the molecular profile of their melanoma.
- Medical Oncologist and MIA’s Co-Medical Director Prof Georgina Long AO will be delivering a keynote address discussing if a cure for advanced melanoma is on the horizon. She will review the recent advancements in drug development to treat advanced melanoma, as well as outline the challenges we still face to overcome drug resistance. Prof Long will also highlight the importance of getting our prevention messaging across if we truly want to reach our goal of zero deaths from melanoma.
- Translational researcher Prof Helen Rizos will be reviewing how circulating DNA in the bloodstream can be used as a marker to monitor disease and treatment response in patients with advanced melanoma. This minimally invasive technique can help monitor patients in real-time and is proving to be a valuable new tool to support the clinical care of patients with melanoma.
- Dermatologist Prof Diona Damian will be presenting an overview of nicotinamide (vitamin B3) as a preventative measure to reduce the incidence of non-melanoma skin cancers in high-risk patients.
- Using clinical data alone can help predict which patients will respond well to treatment with immunotherapy. However, when Dr James Wilmott and our team of lab researchers examined biopsies taken from patients before immunotherapy, they found that biopsies showing higher numbers of immune cells touching the melanoma were associated with response and tumour shrinkage. Dr Wilmott will share these findings which will ultimately help select the ideal therapies for patients and will be incorporated into our Personalised Immunotherapy Platform.
Through the combined sharing of knowledge, it is inspiring to see the global commitment to enhancing our understanding of melanoma that will ultimately improve the care of melanoma patients.
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.
Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.
Melanoma research at ASCO this year focussed on the more precise use of current treatments to ensure optimal treatment for each patient.
MIA recently demonstrated that reflectance confocal microscopy is a useful tool in the clinic to diagnose suspicious-looking lesions in the mouth.
New research is likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost.
Researchers from MIA will present their latest research findings to the world’s largest oncology conference in early June.
Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours
Australian researchers are the first to demonstrate that patients with advanced melanoma which has spread to the brain can have increased life expectancy and possibly even beat the disease.
Melanoma March 2017 - that's a wrap! Thank you to everyone that helped make it happen.
Thank you so much to all those who contributed in a variety of ways to Melanoma March 2017 in 17 different locations and more around the country! You have contributed to getting the Big Data for Melanoma national Research Project happening!
By looking at the ‘dark matter’ of the genome, new research has found that genetic changes in acral and mucosal melanoma are completely different to mutations found in skin melanoma.
‘Slip, slop, slap’ is synonymous with being Australian and playing it safe in the sun. These sun smart rules reduce our chances of getting melanoma of the skin. However, new research tells a different story for those affected by rarer forms of melanoma.